News & Updates

Show Multimedia Only

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit

25 Feb 2024 by

Combination treatment with durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) leads to higher rates of pathologic complete response (pCR) in patients with resectable gastric cancer (GC) or gastroesophageal junction cancer (GEJC), with the benefit universally observed regardless of geographic location, according to the subgroup analysis of the phase III MATTERHORN study.

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit

25 Feb 2024

Apixaban recommended for blood clot prevention in gynaecologic cancer surgery

25 Feb 2024

Prophylactic apixaban appears to effectively reduce the risk of venous thromboembolism (VTE) for patients undergoing open surgery for gynaecologic malignancies and should be considered the standard of care for VTE prophylaxis in this population, according to a retrospective study.

Apixaban recommended for blood clot prevention in gynaecologic cancer surgery

25 Feb 2024

Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer

24 Feb 2024 by

First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.

Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer

24 Feb 2024

Methylnaltrexone proves safety in paediatric oncology patients with constipation

24 Feb 2024

Subcutaneous methylnaltrexone is safe to use in children with cancer who have opioid-induced constipation, suggest the results of a study. In addition, this agent stimulates bowel movements in more than a third of paediatric patients.

Methylnaltrexone proves safety in paediatric oncology patients with constipation

24 Feb 2024

Patients on anticancer therapeutic agents may develop carpal tunnel syndrome

23 Feb 2024

Carpal tunnel syndrome (CTS) is not uncommon in patients being treated with anticancer therapeutic agents, reports a study. Electrodiagnostic (EDX) studies and ultrasound (US) are necessary in the diagnostic assessment of these individuals.

Patients on anticancer therapeutic agents may develop carpal tunnel syndrome

23 Feb 2024

Thoracoscopic esophagectomy better than open surgery in esophageal cancer

23 Feb 2024 by

Thoracoscopic esophagectomy (TE) has demonstrated its noninferiority to open transthoracic esophagectomy (OE) for patients with thoracic esophageal cancer in a study presented at ASCO GI 2024.

Thoracoscopic esophagectomy better than open surgery in esophageal cancer

23 Feb 2024

Abiraterone vs docetaxel in Asian mHSPC patients: What’s the difference?

23 Feb 2024 by

A real-world analysis of 574 Asian patients with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrated a significantly longer progression-free survival (PFS) and similar overall survival (OS) with abiraterone plus androgen deprivation therapy (ADT) vs docetaxel plus ADT.

Abiraterone vs docetaxel in Asian mHSPC patients: What’s the difference?

23 Feb 2024

Stroke risk high among head and neck cancer survivors in SG

22 Feb 2024 by

Survivors of head and neck cancer (HNC) in Singapore have a more than twofold increased risk of stroke, regardless of age, cancer subsites, and treatment modalities, among others, according to a study.

Stroke risk high among head and neck cancer survivors in SG

22 Feb 2024

Veterans with higher traumatic brain injury predisposed to subsequent brain cancer

21 Feb 2024

Veterans of Iraq and Afghanistan who sustained moderate/severe and penetrating traumatic brain injury (TBI) are at increased risk of developing brain cancer, as shown in a study.

Veterans with higher traumatic brain injury predisposed to subsequent brain cancer

21 Feb 2024

5-year survival more likely in mBCC patients with nodal vs distant metastasis

21 Feb 2024

Among patients with metastatic basal cell carcinoma (mBCC), those with nodal disease appear to have a higher chance of remission, while individuals with distant metastasis tend to have persistent disease and subsequently die from it, a recent study reveals. However, the survival rates at 5 years surpass 50 percent even for those with stage IV disease.

5-year survival more likely in mBCC patients with nodal vs distant metastasis

21 Feb 2024

News & Updates

Showing Oncology articles

Showing

Specialty:

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit

Durvalumab plus chemo for GC/GEJC delivers globally consistent benefit

Apixaban recommended for blood clot prevention in gynaecologic cancer surgery

Apixaban recommended for blood clot prevention in gynaecologic cancer surgery

Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer

Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer

Methylnaltrexone proves safety in paediatric oncology patients with constipation

Methylnaltrexone proves safety in paediatric oncology patients with constipation

Patients on anticancer therapeutic agents may develop carpal tunnel syndrome

Patients on anticancer therapeutic agents may develop carpal tunnel syndrome

Thoracoscopic esophagectomy better than open surgery in esophageal cancer

Thoracoscopic esophagectomy better than open surgery in esophageal cancer

Abiraterone vs docetaxel in Asian mHSPC patients: What’s the difference?

Abiraterone vs docetaxel in Asian mHSPC patients: What’s the difference?

Stroke risk high among head and neck cancer survivors in SG

Stroke risk high among head and neck cancer survivors in SG

Veterans with higher traumatic brain injury predisposed to subsequent brain cancer

Veterans with higher traumatic brain injury predisposed to subsequent brain cancer

5-year survival more likely in mBCC patients with nodal vs distant metastasis

5-year survival more likely in mBCC patients with nodal vs distant metastasis